Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome II + gemcitabine + nab-paclitaxel + adalimumab for conversion therapy in locally advanced pancreatic cancer (Phase 2)
ChiCTR2500108269Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Irinotecan liposome II, gemcitabine, paclitaxel and adalimumab in pancreatic cancer (PC), sponsored by Chinese PLA General Hospital. Primary endpoint: Conversion rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2500108269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108269.